These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16271338)

  • 1. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.
    Hirano I; Zhang Q; Pandolfino JE; Kahrilas PJ
    Clin Gastroenterol Hepatol; 2005 Nov; 3(11):1083-8. PubMed ID: 16271338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
    Garrean CP; Zhang Q; Gonsalves N; Hirano I
    Am J Gastroenterol; 2008 Jul; 103(7):1631-7. PubMed ID: 18557714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
    Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
    Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
    Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K
    Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
    Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus.
    Yachimski P; Maqbool S; Bhat YM; Richter JE; Falk GW; Vaezi MF
    Am J Gastroenterol; 2015 Aug; 110(8):1143-8. PubMed ID: 26032153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Day-to-day variability in acid reflux patterns using the BRAVO pH monitoring system.
    Ahlawat SK; Novak DJ; Williams DC; Maher KA; Barton F; Benjamin SB
    J Clin Gastroenterol; 2006 Jan; 40(1):20-4. PubMed ID: 16340628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.
    Gerson LB; Triadafilopoulos G; Sahbaie P; Young W; Sloan S; Robinson M; Miner PB; Gardner JD
    BMC Gastroenterol; 2008 May; 8():15. PubMed ID: 18498663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Adachi K; Hashimoto T; Hamamoto N; Hirakawa K; Niigaki M; Miyake T; Taniura H; Ono M; Kaji T; Suetsugu H; Yagi J; Komazawa Y; Mihara T; Katsube T; Fujishiro H; Shizuku T; Hattori S; Yamamoto S; Kinoshita Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1392-8. PubMed ID: 14675268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
    Gerson LB; Shetler K; Triadafilopoulos G
    Dig Liver Dis; 2005 Sep; 37(9):651-8. PubMed ID: 15919250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Additional Role of Symptom-Reflux Association Analysis of Diagnosis of Gastroesophageal Reflux Disease Using Bravo Capsule pH Test].
    Jung K; Park MI; Park SJ; Moon W; Kim SE; Kim JH
    Korean J Gastroenterol; 2017 Oct; 70(4):169-175. PubMed ID: 29060954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
    Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
    Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model to Select On-Therapy vs Off-Therapy Tests for Patients With Refractory Esophageal or Extraesophageal Symptoms.
    Patel DA; Sharda R; Choksi YA; Slaughter JC; Higginbotham T; Garrett CG; Francis DO; Ravi K; Hasak S; Katzka D; Gyawali CP; Vaezi MF
    Gastroenterology; 2018 Dec; 155(6):1729-1740.e1. PubMed ID: 30170117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Jul; 18(1):133-40. PubMed ID: 12848635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.